Table 3. Univariate survival analysis of OS in patients with NSCLC.
| HR | 95.0% CI for HR |
P | ||
|---|---|---|---|---|
| Lower | Upper | |||
| Gender | ||||
| Male | 1.000 | |||
| Female | 0.656 | 0.455 | 0.946 | 0.024 |
| Age | ||||
| <65 | 1.000 | |||
| ≥65 | 1.279 | 0.908 | 1.802 | 0.160 |
| Tumor stage | ||||
| T1 | 1.000 | |||
| T2 | 0.693 | 0.369 | 1.299 | 0.252 |
| T3 | 1.084 | 0.544 | 2.161 | 0.819 |
| T4 | 1.180 | 0.676 | 2.062 | 0.560 |
| Lymph node metastasis | ||||
| N0 | 1.000 | |||
| N1 | 0.762 | 0.339 | 1.716 | 0.512 |
| N2 | 0.907 | 0.557 | 1.476 | 0.693 |
| N3 | 1.122 | 0.669 | 1.881 | 0.663 |
| Pleural effusion | ||||
| No | 1.000 | |||
| Yes | 1.967 | 1.167 | 3.317 | 0.011 |
| TNM stage | ||||
| III | 1.000 | |||
| IV | 1.504 | 1.027 | 2.203 | 0.036 |
| Smoking | ||||
| <20 | 1.000 | |||
| ≥20 | 1.217 | 0.865 | 1.712 | 0.259 |
| ECOG PS | ||||
| 0-1 | 1.000 | |||
| >1 | 9.420 | 3.721 | 23.846 | 0.000 |
| Histology | ||||
| Adenocarcinoma | 1.000 | |||
| Squamous | 1.298 | 0.900 | 1.871 | 0.163 |
| Others | 0.466 | 0.203 | 1.070 | 0.072 |
| PLR | ||||
| <152.6 | 1.000 | |||
| ≥152.6 | 1.867 | 1.328 | 2.625 | 0.000 |
OS, overall survival; NSCLC, non-small cell lung cancer; CI, confidence interval; HR, Hazard ratio; TNM, tumor lymph node metastasis; ECOG, the eastern cooperative oncology group; PS, performance status; PLR, platelet-to-lymphocyte ratio.